ArticleMolecular neurobiology2026
Synergistic Efficacy of Lactobacillus plantarum Supernatant-Preconditioned BM-MSCs in Alleviating Depression, Anxiety-Like Behavior, and Memory Impairment in a Rat Stress Model by Suppressing the NF-κB Pathway.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs)-based therapy has received considerable research attention for its anti-inflammatory properties in depressive-like behavior, but poor MSC survival and immunogenicity after transplantation limit their therapeutic effectiveness. This study evaluated pretreated bone marrow-derived MSCs (BM-MSCs) with Lactobacillus plantarum supernatant (L.PS) in an animal model of chronic restraint stress (CRS)-induced depressive-like behavior. BM-MSCs were pretreated with 15 μM of fluoxetine (Flx) or 10 µl/ml of L.PS for 24 h. Thirty-six adult male Wistar rats were divided into six groups: CTRL, CRS, CRS + PBS (Phosphate-Buffered Saline), CRS + MSCs, CRS + MSCs(Flx) (Flx-preconditioned MSCs), and CRS + MSCs(L.PS) groups. The open field test, Morris water maze, forced swimming test, body weight, and blood glucose levels were measured. After sacrifice, the hippocampal tissues underwent histopathological analysis. Additionally, hippocampal mRNA levels of NF-κB and pro-inflammatory cytokines (IL-1β, IL-6, IL-18, and TNF-α) were measured using real-time PCR, while ELISA was used to measure protein levels of these cytokines and serum corticosterone. A bioinformatic analysis, including protein-protein interaction network, enrichment, and correlation analysis related to depression, was performed. Pre-treatment of MSCs with L.PS significantly improved depressive-like behavior (p < 0.05) by enhancing MSCs neuroprotection through the downregulation of NF-κB and pro-inflammatory cytokines. An in silico analysis also supported the importance of evaluating and targeting this pathway. In conclusion, we found that L.PS pretreated MSCs significantly improves CRS-induced depressive-like behavior, which can be partly attributed to the inhibition of NLRP3-mediated neuroinflammation.
Indexed as
Identifiers
41610001What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.